About Sensigen
Sensigen is a Healthcare company based in United States founded in 2002, and was acquired by Sequenom in January 2009. Womens health and genetic testing services are provided with support. Its focus areas include Life Sciences, Genomics, Applied Genomics and Consumer Genomics.
Company details
Sensigen was founded in 2002 and is based in Research Triangle Park, United States. Operations focus on the womens health sector, where genetic testing services are offered for areas including hereditary cancer, pre-pregnancy, pregnancy, pediatric, and sexual health. Genetic counseling and resources are provided to patients and healthcare providers. Advanced diagnostics and screening options are supported for healthcare professionals.
- Headquarters Research Triangle Park, United States
- Stage Acquired
- SectorsHealthcare
- Website sensigen.com
- Acquired by Sequenom (Jan 2009)
Investors in Sensigen
Sensigen has secured backing from 1 investor. Prominent investors backing the company include Sequenom.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Noninvasive prenatal testing using cell-free fetal nucleic acids is offered. | 1994 | sequenom.com | San Diego, United States |
Investor details for Sensigen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Sensigen
2 dated milestones of Sensigen across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Sensigen is founded.
- Exit Acquired by Sequenom.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Sensigen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sensigen
Sensigen was founded in 2002.
Sensigen is headquartered in United States. It is registered at North Carolina, United States.
Sensigen was founded in 2002 and is based in Research Triangle Park, United States. Operations focus on the womens health sector, where genetic testing services are offered for areas including hereditary cancer, pre-pregnancy, pregnancy, pediatric, and sexual health. Genetic counseling and resources are provided to patients and healthcare providers. Advanced diagnostics and screening options are supported for healthcare professionals.
Sensigen has 1 investor. Key investors include Sequenom.
Yes. Sensigen was acquired by Sequenom in January 2009.